Gutiérrez LA, Ponte GG, Leyva QA, Valdés RM

Idioma: Español
Referencias bibliográficas: 30
Paginas: 177-182
Archivo PDF: 403.94 Kb.

RESUMEN

La aldosterona constituye uno de los componentes del sistema renina-angiotensina-aldosterona. Existen elementos teóricos y evidencia clínica de su relación con las enfermedades del corazón. Se revisaron numerosas referencias bibliográficas con el objetivo de describir las principales características de la aldosterona y su relación con estas enfermedades. Tradicionalmente se ha pensado que la acción de la aldosterona se restringía tanto a la reabsorción de sodio y agua, como a la excreción de potasio a nivel renal. En años recientes se ha demostrado que desempeña una función primordial en muchos procesos de la patogenia de la enfermedad arterial coronaria y los remodelados cardíaco y vascular.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Kumar R, Singh VP, Baker KM. The intracellular renin-angiotensin system: a new paradigm. Trends Endocrinol Metab. 2007;18:208-14.

2. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008;57:3297-306.

3. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med. 2009;150:776-83.

4. Rhee SS, Pearce EN. Sistema endocrino y corazón: una revisión. Rev Esp Cardiol. 2011;64:220- 31.

5. Williams JS, Williams GH. 50th anniversary of aldosterone. J Clin Endocrinol Metab. 2003;88: 2364-72.

6. Messaoudi S, Jaisser F. Aldosterone and the mineralocorticoid receptor. Eur Heart J. 2011; 13(Suppl B):4-9.

7. Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013;9:459-69.

8. Messaoudi S, Azibani F, Delcayre C. Aldosterone, mineralocorticoid receptor, and heart failure. Mol Cell Endocrinol. 2012;350:266-72.

9. Funder JW. Reconsidering the roles of the mineralocorticoid receptor. Hypertension. 2009;53:286- 90.

10. Zannad F, Gattis Stough W, Rossignol P, Bauersachs J, McMurray JJ, Swedberg K, et al. Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J. 2012;33: 2782-95.

11. Rocha R. Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol. 2002;283:H1802-10.

12. Connell JM, Davies E. The new biology of aldosterone. J Endocrinol. 2005;186:1-20.

13. Pitt B, Stier CT, Rajagopalan S. Mineralocorticoid receptor blockade: new insights into the mechanism of action in patients with cardiovascular disease. J Renin Angiotensin Aldosterone Syst. 2003;4:164-8.

14. Contra HS, Estrada LR, Chávez, AG, Hernández H. El sistema renina-angiotensina-aldosterona y su papel funcional más allá del control de la presión arterial. Rev Mex Cardiol. 2008;19:21-9.

15. Christ M, Meyer C, Sippel K, Wehling M. Rapid aldosterone signaling in vascular smooth muscle cells: involvement of phospholipase C, diacylglycerol and protein kinase C alpha. Biochem Biophys Res Commun. 1995;213:123-9.

16. Grossmann C, Gekle M. New aspects of rapid aldosterone signaling. Mol Cell Endocrinol. 2009; 308:53-62.

17. Fuller PJ, Yao Y, Yang J, Young MJ. Mechanism of ligand specificity of the mineralocorticoid receptor. J Endocrinol. 2012;213:15-24.

18. Briet M, Schiffrin EL. Aldosterone effects on the kidney and cardiovascular system. Nat Rev Nephrol. 2010;6:261-73.

19. Briet M, Schiffrin EL. The role of aldosterone in metabolic syndrome. Curr Hypertens Rep. 2011; 13:163-72.

20. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W. Plasma aldosterone levels are asso-ciated with increased cardiovascular mortality: the Ludwigshafen Risk and Cardiovascular Health (LURIC) study. Eur Heart J. 2010;31:1237-47.

21. Ivanes F, Susen S, Mouquet F, Pigny P, Cuilleret F, Sautière K, et al. Aldosterone, mortality, and acute ischaemic events in coronary artery dis-ease patients outside the setting of acute myocar-dial infarction or heart failure. Eur Heart J. 2012; 33:191-202.

22. Amano T, Matsubara T, Izawa H, Torigoe M, Yo-shida T, Hamaguchi Y, et al. Impact of plasma aldosterone levels for prediction of in-stent reste-nosis. Am J Cardiol. 2006;97:785-8.

23. De Rita O, Hackam DG, Spence JD. Effects of aldosterone on human atherosclerosis: plasma aldosterone and progression of carotid plaque. Can J Cardiol. 2012;28:706-11.

24. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation. 2000;101:2981-8.

25. Leopold JA. Aldosterone, mineralocorticoid re-ceptor activation, and cardiovascular remodeling. Circulation. 2011;124:e466-8.

26. Zwadlo C, Bauersachs J. Mineralocorticoid recep-tor antagonists for therapy of coronary artery disease and related complications. Curr Opin Pharmacol. 2013;13:280-6.

27. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L. Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation. 1990;82:1730-6.

28. Brilla CG, Matsubara LS, Weber KT. Anti-aldos-terone treatment and the prevention of myocar-dial fibrosis in primary and secondary hyperal-dosteronism. J Mol Cell Cardiol. 1993;25:563-75.

29. Le Menuet D, Isnard R, Bichara M, Viengchareun S, Muffat-Joly M, Walker F, et al. Alteration of cardiac and renal functions in transgenic mice overexpressing human mineralocorticoid recep-tor. J Biol Chem. 2001;276:38911-20.

30. Bauersachs J. Aldosterone antagonism in heart failure: improvement of cardiac remodelling, en-dothelial dysfunction and platelet activation. Eur J Clin Invest. 2004;34:649-52.